Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

The biotech announced this morning that its dose-ascending Phase I/II study of its lead gene therapy for Duchenne muscular dystrophy flopped, sending the company into overdrive to hustle a higher dose into the clinic.